Table 4. Current disease status of... | American Society of Hematology

Table 4.

Current disease status of patients with type II diabetes mellitus

	Bgl II (+/+)	Bgl II (+/−)	Bgl II (−/−)	P Value
Patients without retinopathy or nephropathy (group A)
HbA_1C (%, mean ± SD)	7.1 ± 1.2	7.8 ± 1.4	7.6 ± 1.3	.2620^4-150
Prevalence of antihypertensive drug treatment (%)	38.5	23.4	14.6	.1572^4-151
Hyperlipidemia (%)	46.2	51.1	47.9	.9303^4-151
Patients with retinopathy or nephropathy (group B + C)
HbA_1C (%, mean ± SD)	8.3 ± 1.6	7.9 ± 1.5	8.3 ± 1.6	.3827^4-150
Prevalence of antihypertensive drug treatment (%)	58.3	50.8	63.9	.4502^4-151
Hyperlipidemia (%)	25.0	42.4	47.2	.2063^4-151

	Bgl II (+/+)	Bgl II (+/−)	Bgl II (−/−)	P Value
Patients without retinopathy or nephropathy (group A)
HbA_1C (%, mean ± SD)	7.1 ± 1.2	7.8 ± 1.4	7.6 ± 1.3	.2620^4-150
Prevalence of antihypertensive drug treatment (%)	38.5	23.4	14.6	.1572^4-151
Hyperlipidemia (%)	46.2	51.1	47.9	.9303^4-151
Patients with retinopathy or nephropathy (group B + C)
HbA_1C (%, mean ± SD)	8.3 ± 1.6	7.9 ± 1.5	8.3 ± 1.6	.3827^4-150
Prevalence of antihypertensive drug treatment (%)	58.3	50.8	63.9	.4502^4-151
Hyperlipidemia (%)	25.0	42.4	47.2	.2063^4-151

F4-150

Calculated by ANOVA, differences in values are compared among the three genotypes in patients without retinopathy or nephropathy, or among the three genotypes in patients with retinopathy or nephropathy.

F4-151

Calculated by chi-square test, 2 × 3 contingency table.

View Large

This Feature Is Available To Subscribers Only